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Micronutrients, an umbrella term used to collectively describe vitamins and trace 17 
elements (TEs), are essential components of nutrition. Those requiring alternative 18 
forms of nutrition support are dependent on the prescribed nutrition regimen for their 19 
MN provision. The purpose of this document is to assist clinicians to bridge the gap 20 
between the available guidelines’ recommendations and their practical application in 21 
the provision of micronutrients via the parenteral route to adult patients. 22 
Methods:  23 
Based on the available evidenced-based literature and existing guidelines, a panel of 24 
multidisciplinary healthcare professionals with significant experience in the provision of 25 
parenteral nutrition and intravenous micronutrients developed this international 26 
consensus paper.  27 
Results: 28 
The document addresses 14 pertinent questions regarding the clinical importance and 29 
use of in various clinical conditions. Practical guidelines on how micronutrients should 30 
be prescribed, administered and monitored are provided. 31 
Conclusion: 32 
Micronutrients are a critical component to nutritional provision and PN provided 33 
without them pose a considerable risk to nutritional status. Obstacles to their daily 34 
provision - including voluntary omission, partial provision and supply issues - must be 35 
overcome to allow safe and responsible nutrition practice. 36 
 37 
 38 
  39 







Introduction and purpose of the paper 6 
 7 
Micronutrients – that is, vitamins and trace elements (TEs) - are essential components of 8 
nutrition. While they are provided by a varied diet to the general population, those requiring 9 
alternative forms of nutrition support are dependent on the prescribed nutrition regimen for 10 
their micronutrient provision.  11 
 12 
 13 
Although the importance of micronutrients has been known for decades, the use of vitamin 14 
and TE admixtures with parenteral nutrition (PN) is often not a routine process, because of the 15 
misconception that PN providing macronutrients is “total”. The conviction prevails that despite 16 
obvious malabsorption in short bowel patients, diet and oral micronutrient supplements can 17 
meet the requirements of patients who are able to eat, but nevertheless depend on PN. 18 
However, this can be partly true only if the proximal small bowel is still functionally active. 19 
Additionally, the lack of reliable assessment for the clinical status of several micronutrients, 20 
access to these laboratory measurements, and standardization of techniques in quantifying 21 
Micronutrients, make it difficult in most settings to monitor micronutrient levels. Costs and 22 
difficulties obtaining remuneration for micronutrient provision, as administrators have trouble 23 
paying for what they regard as a “supplement” can also be a factor, as well as a lack of 24 
awareness about the importance of micronutrients in metabolism and the need to prescribe it 25 





These are some of the reasons a number of multidisciplinary nutrition societies have developed 31 
guidelines to help clinicians navigate the issues around the prescription, administration and 32 
monitoring of micronutrients in both short (< 3-4 weeks) and long term PN (> 4 weeks)1. 33 
However, a discrepancy between the recommendations in these guidelines and current clinical 34 
practice is acknowledged. Also, when guidelines formulated for specific locations are 35 
attempted to be implemented outside of the intended region, it can result in confusion (e.g. 36 
guidelines quoting specific products which are often not available outside of that region or the 37 




The purpose of this international consensus paper is to assist clinicians to bridge the gap 42 
between the available guidelines’ recommendations and their practical application in the 43 
provision of micronutrients via the parenteral route to adult patients. Therefore, the primary 44 
intended audience is clinicians prescribing PN to adults, and secondarily the organisations and 45 
health services in which PN is being utilised to support safe PN practice. It is hoped that in 46 
making clear the practice application of the guidelines this expert consensus paper will assist in 47 
guiding international practices in PN provision to the evidence based guidelines available, and 48 
to serve as a platform for clinicians, organisations and regions to advocate for access to the 49 
resources required to administer PN safely.  50 
 51 
 52 
This paper is not intended to provide a comprehensive systematic review of all aspects of 53 
intravenous (IV) micronutrients, although where clinically relevant, micronutrient provision 54 











be addressed. Where the depth of relevant clinical content is out of scope of this paper, 4 
readers will be directed to more comprehensive references to obtain further information.  5 
 6 
The views presented here reflect the interpretation of the literature and existing guidelines by 7 
clinicians with significant experience in the provision of PN in a range of contexts from different 8 
geographic locations around the world. The information presented will be limited to adult 9 
patients due to the differences in physiology, metabolism, requirements and nutritional goals 10 
in the pediatric population. The following micronutrients have been addressed: fat soluble 11 
(vitamins A, D, E, K) and water-soluble (vitamins B and C) vitamins, and trace elements (TEs) 12 
copper (Cu), iodine (I), Iron (Fe), selenium (Se), zinc (Zn), chromium (Cr), manganese (Mn) and 13 
molybdenum (Mo). Fluoride is available in some markets for addition to PN sformulations 14 
where indicated, however the majority of patients meet their requirements through 15 
fluoridated beverages (including water). Due to flouride not being a routine addition to PN, it 16 





A panel of multidisciplinary healthcare professionals recognised as experts in the provision of 22 
PN and IV micronutrients were invited to participate in the development of an international 23 
consensus statement. Initial face to face meetings were held for various regional clusters 24 
(North America, Latin America, Europe and Africa, and Asia Pacific), where the scope and 25 
planning of the statement were discussed. The individual inputs incorporate literature searches 26 
through MEDLINE (accessed via PubMed) and personal databases. Thereafter the panel 27 
functioned remotely through the facilitation of a steering committee (RB, KS, EO) which 28 
designed and compiled the framework of the document. The final paper was compiled based 29 
on input received from all members. It was circulated for comments and consensus within the 30 





Hereafter the word supplementation will be used when the aim is to achieve supra-normal 36 
levels, including pharmaconutrition attempts. Complementation will be used to indicate the 37 
delivery of micronutrients to cover basal needs in case of low macro-substrate intakes (e.g. to 38 
complete enteral feeds or PN). Repletion will be used when deficiency or losses are identified 39 




Dietary recommended intakes (DRI) although intended for enteral use will be used to indicate 44 




Q1: Why are micronutrients important? 49 
 50 
Recommendation:  51 
Micronutrients are essential for the metabolism and utilization of macronutrients and affect 52 
virtually every enzyme system in the body. As such, they constitute a crucial component of 53 
nutrition therapy and should be consumed in the recommended amounts daily. 54 
 55 
 56 
Rationale:  57 
Micronutrients play important roles in intermediary metabolism through their function as 58 
cofactors in enzymes and as co-enzymes, antioxidant systems and gene transcription. 59 
Micronutrients act in concert  60 









with one another. PN provided without proportionate micronutrients over time will result in 8 
the development of deficiency, metabolic dysfunction, and in some cases, death.  9 
 10 
 11 
A full description of the primary role and function of individual micronutrients and the clinical 12 
manifestations of deficiency states are outside the scope of this consensus paper. Full 13 
micronutrient monographs can be found in a publication by Sriram and Lonchyna2 . 14 
 15 
 16 
Q2: What is the history of micronutrients in parenteral nutrition? 17 
 18 
The awareness about micronutrients needs in PN goes back to the 1970s. PN was developed in 19 
the 1950s and early 1960s3, as a combination of three distinct components: amino acids, 20 
glucose, and finally lipid emulsions in 1961. The initial amino acid solutions were prepared by 21 
acid hydrolysis of so called “high quality proteins” such as casein. Later, the preparations were 22 
purified by dialysis, until the synthesis in 1964 of crystalline amino acids. Due to the purification 23 
process, the amino acid solutions became deficient in TEs and vitamins, which resulted in 24 




Trace Elements:  Kay et al4 published a case series of 37 adult patients in 1976, in whom Zn 29 
deficiency was diagnosed after 3 weeks of PN. The combination of diarrhea, mental depression, 30 
para-nasal, oral and peri-oral dermatitis, and alopecia, was called the Zn deficiency syndrome. 31 
These symptoms were reversed by the administration of Zn.5 A case of reversible Cr deficiency 32 
presenting with peripheral neuropathy and severe glucose intolerance after 5 years of PN was 33 
published. All symptoms resolved with Cr administration.5 In 1977, Jacobson et al6 studied the 34 
balances of 20 TEs during PN in 4 male patients who were receiving additional Cu, fluoride (F), 35 
Fe, I, Mn, and Zn. The authors observed unintentional administration of several non-prescribed 36 
TEs, due to contamination of the solutions. The authors also observed a decline of the serum 37 
concentrations of 13 TEs (including Cu, Fe, Mo, Se and Zn), corresponding to the negative 38 
balance values. Based on their findings, the authors wrote the first recommendation to 39 
administer systematically TEs with PN.7 In 1979, the American Medical Association published 40 
the first guidelines for essential TE provision during PN.8  41 
Vitamins:  While the FDA had validated an adult formulation for 9 water-soluble and 4 lipid-42 
soluble vitamins in 19799, awareness about potential vitamin deficiency during PN came later, 43 
with the diagnosis of cardiac failure with lactic acidosis in patients after 4 weeks of PN.10 44 
Awareness about deficiencies occurred simultaneously in the US and Europe.11 Cases of 45 
Wernicke’s encephalopathy were described.12 Labadarios et al showed that several vitamins 46 
exhibited a deficiency pattern after prolonged PN despite the administration of available IV  47 
multivitamin (MV) products.13 Vitamins of the B group, vitamin C, A and D were low in 40 to 48 







In 2009, an American workshop analyzed the available vitamin and TE solutions.14 While the 56 
product contents were considered sufficient for stable patients, concerns were formulated as 57 
to the unavailability of separate vitamin and TE solutions to face increased needs. The reality of 58 
TE and vitamin administration in clinical settings was questioned. This led the European Society 59 
for Clinical Nutrition and Metabolism (ESPEN) to make a formal statement in 2009 about the  60 
 61 









necessity to  systematically prescribe one MV and one multiple trace element (MTE) 8 
preparation for each single day of PN.15 This statement was recently reinforced by a meta-9 
analysis.16 In 2012, an American Society for Parenteral and Enteral Nutrition (ASPEN) statement 10 
was published.17 It again stated that the parenteral MV and MTE preparations, available in the 11 
U.S, met the requirements for most PN patients but the development of new products 12 
addressing specific needs was required. Recommendations included the reduction of Mn and 13 
Cr and the addition of choline to commercial MTE preparations, and the development of a 14 
separate injectable vitamin D. The available parenteral MTE preparations were considered to 15 
require revision. These recommendations have not been implemented to date. Guidelines 16 
developed by AuSPEN for Australia and New Zealand endorsed similar changes to 17 
recommendations and MTE preparations in their market.18 19 Finally, the 2018 ESPEN guidelines 18 











Yes, there are mainly three additional situations during which micronutrient administration 30 
may be needed in the absence of PN. These include conditions associated with specific losses, 31 
oxidative stress and situations where inadequate enteral nutrition is provided. 32 
 33 
 34 
Rationale:  35 
In cases where PN is not indicated, or in cases where it is not the sole route of nutritional 36 
provision, alternative micronutrient supplementation/replacement options may exist enterally 37 
or orally. It is, however, beyond the scope of this paper to discuss enteral micronutrient 38 
replacement. For this purpose of this paper the discussion will be focused on IV replacement 39 
routes in the context of PN, or in cases where enteral routes are not sufficient or reliable to 40 
deliver the intended doses. 41 
1) Specific losses: Some medical interventions, such as dialysis and continuous renal 42 
replacement therapy (CRRT), cause significant TE losses. Prolonged CRRT has a  particularly 43 
negative impact on Cu status, causing severe clinical deficiency.20–22 Patients with high 44 
output intestinal fistula, ostomy effluent, or severe diarrhea can have significant Zn losses 45 
- up to 12 mg/L for small bowel effluent and 17 mg/L in stool output. 23 Major burns are 46 
also characterized by micronutrients containing exudative losses warranting careful 47 
monitoring and supplementation.22 48 
2) Oxidative stress: Several acute pathologies are characterized by increased oxidative stress, 49 
consuming the available endogenous antioxidants. Several studies have attempted to 50 
restore antioxidant defense with very high doses of IV Se (10 to 100 times the DRI). 51 
Recently it was shown that such isolated administration of one single TE was not 52 
associated with any significant benefit.24 The case for high dose ascorbic acid (200 53 
mg/kg/24 h) in septic shock during the first 72 hours, however, seems promising25, and 54 
phase III trials are in progress. In major burns resuscitation the administration of high dose 55 
ascorbic acid has been associated with reduction of fluids required. These micronutrient 56 
interventions, affecting endothelial function and other inflammation related responses, 57 
cannot be considered as nutrition and therefore should be categorized as  pharmaco-58 
nutrition.26 (Please refer to Q5 and Q6). 59 
3) Patients on enteral nutrition (EN) may not receive the DRI amounts of micronutrients for 60 
several reasons. In the acute care setting, EN is frequently interrupted for various procedures 61 
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and tests or slow progressive feeding to target. This results in nutrition targets not being 1 
and/or energy needs less than 1500 kcal/day. In these cases patients are likely to receive 2 
insufficient daily amounts of micronutrients, as most commercial solutions meet daily 3 
micronutrient requirements only when 1-1.5 litre of product (± 1500 kcal) is administered.22 27 4 
Further, enteral absorption is variable, particularly during critical illness and in other 5 




These conditions may justify the temporary administration of IV micronutrients at doses 10 
sufficient to cover basal metabolic needs during the acute phase of disease, i.e. the first 5-7 11 
days, when EN is not yet at full requirements28, especially in those patients with prior poor 12 
nutritional status or suspected gastrointestinal malabsorption. 13 
 14 
 15 
Q4: Is there a need to provide intravenous micronutrients to critically ill patients? 16 
 17 
Recommendation:  18 
During metabolic stress, reprioritization of micronutrients occurs to support the acute phase 19 
response, with a redistribution of micronutrients out of the circulating compartment. It is 20 
important to interpret blood concentrations below reference range within the context and the 21 
degree of the acute phase response. Therefore, serum C-reactive protein (CRP) levels should 22 




As most patients are enterally fed, the provision of additional micronutrient should follow 27 
recommendations described in question 3. In those receiving PN support, daily IV MV and MTE 28 
provision avoids/delays the development of micronutrient deficiencies. For critically ill patients 29 
with specific identified micronutrient deficiency risks, additional supplementation may need to 30 
be considered and the use of higher doses of IV micronutrients, either as part of PN provision or 31 
as a standalone intervention, may be warranted. 32 
 33 
Rationale:  34 
Critical illness represents an extreme form of metabolic stress, which exhibits a phased 35 
response (ebb followed by flow phase).29  Physiologically the metabolic changes associated 36 
with metabolic stress are referred to as the acute phase response.  37 
 38 
 39 
The acute phase response affects micronutrients by increasing requirements (due to increased 40 
catabolism, increased losses, decreased intake and increased usage) and by redistributing the 41 
micronutrients due to the release of pro-inflammatory cytokines.2,19,29–32 This results in altered 42 
serum concentrations and decreased total body reserve.2 It is important to determine the 43 
cause of decreased circulating levels in order to correctly treat the situation. The plasma 44 
concentration of several micronutrients decrease during the systemic inflammatory response 45 
syndrome (SIRS) in critical illness; therefore laboratory tests showing decreased plasma values 46 
may not necessarily reflect a true deficiency.32,33 Provided they have not been administered 47 
prior to blood testing, serum levels of vitamins B1, B2 and B12 provide an accurate reflection of 48 
deficiency, since they are not affected by inflammation. 2 Sequestration of TEs in various organs 49 
(mainly liver) results in decreased circulating serum levels. This impacts especially Fe, Se, and 50 
Zn. 2 The impact of metabolic stress on status is depicted in Table 1. 51 
 52 
 53 
Various micronutrient derangements have been described in critically ill patients. Decreased 54 
serum levels do not always indicate actual deficiencies, but rather redistribution and utilisation 55 
which could represent a beneficial adaptive response to critical illness.34 Patients with potential 56 
pre-existing vulnerability should be identified and treated early in the admission, and all 57 
patients receiving  58 
 59 
 60 





PN support in the ICU should be provided daily IV MV and MTE preparations to avoid/delay the 4 
development of micronutrient deficiency.18,19,30  5 
 6 
 7 
Conditions in the ICU that have been associated with micronutrient depletion include sepsis 8 
and SIRS35, burns22, losses from surgical or traumatic wounds23, gastrointestinal (GI) fistulae23 9 
and CRRT20 21 22. Unbalanced and insufficient administration during medical nutrition therapy 10 
throughout the critical care journey places patients at greater risk during these situations.2 11 
Various deleterious consequences have been linked to micronutrient deficiencies, including 12 
poor wound healing, muscle weakness, inadequate immune response and organ dysfunction. 2 13 
30 While the critically ill population represents a heterogeneous group of clinical pathologies, 14 
commonly reported micronutrients of concern include Zn, Fe and Se.2 [Table 2].  15 
 16 
 17 
Due to the impact of the inflammatory response on micronutrient status, micronutrient 18 
concentrations should always be determined in conjunction with parameters reflecting 19 
inflammatory status. 18,19 33 36 CRP is such a parameter and can be used to classify minor (< 10 20 
mg/l), moderate (11-80 mg/l) and major (> 80 mg/l) inflammation.33 21 
 22 
 It is acknowledged that it is very difficult to differentiate between a true micronutrient 23 
deficiency and an inflammation-induced deficiency in the presence of infection. This is an area 24 
of active research and various researchers have proposed different models which include 25 
adjusting micronutrient concentration for albumin status37, plasma retinol concentration 33 38 26 
and using various regression-correction models to account for inflammation.39 Currently there 27 
is no universal approach to account for inflammation when determining micronutrient status.40 28 
 29 
To assist with this dilemma, we propose that interpretation of these results and subsequent 30 
action, needs to differ for acute or chronic conditions.  31 
Acute care: In the case of an acute illness, any deficiency in micronutrient concentrations needs 32 
to be corrected, irrespective of the cause (transient drops in serum levels due to fluxes through 33 
utilisation in metabolic pathways and/or pre-existing deficiency states) in attempt to improve 34 
clinical outcomes. Correction is necessary due to the harmful effects of the micronutrient 35 
deficiencies on antioxidant defense mechanisms, metabolic pathways and general immune 36 
pathways.41 42 CRP in these cases is less relevant because the effect of inflammation is known 37 
and expected, and the supplementation is intended to circumvent the effect of the 38 
inflammation on the serum levels of these micronutrients. 39 
Longer term HPN: The concept is around monitoring of nutritional status and identifying 40 
developing deficiency or toxicity states assumed to be at least in part contributed to (and 41 
therefore ameliorated by modifying) the composition of the HPN formulation. In these cases 42 
knowledge of CRP with respect to micronutrient interpretation is essential to avoid 43 
inadvertently modifying long term provision without due cause, and which may cause 44 
unnecessarily patient expose to harm (ie reducing levels or increasing levels that are artificially 45 
elevated or lowered by an inflammatory response). Therefore, for chronic illness, correction of 46 
a micronutrient deficiency in the presence of infection should be deferred until the 47 
inflammation has been resolved. The micronutrient status needs to be repeated and if still 48 
deficient, supplementation is recommended to restore concentrations. 19  49 
 50 
With CRP increasing over 50 mg/l, the interpretation of the micronutrient levels should be 51 
mitigated and only values <20% below the reference value should be considered indicative of 52 
deficiency. In addition such values should be repeated to observe trends. [Mette, do we have a 53 
reference for the recommendation of < 20% above.  54 
 55 
 56 
Q5: Which intravenous micronutrients are necessary in patients with burns?  57 
 58 
Recommendation:  59 
Most burn patients do not require PN but may need IV micronutrient repletion depending on the 60 
magnitude of the burns injury (see also Questions 1 and 3). If on PN, doses provided through 61 
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standard MTE and MV supplementation are sufficient for smaller burns (<20% body surface 1 
area [BSA]). However higher micronutrient doses are required for major burns, and IV 2 
micronutrient replacement may be warranted independent of PN provision. Antioxidant 3 
micronutrients are probably most important in the first 48hrs, with a transition to wound 4 
healing and immunity during the next 2-3 weeks, followed later during rehabilitation by 5 
prolonged globally increased multi- micronutrient requirements and specific vitamin D needs. 6 
 7 
 8 
Rationale:  9 
Burn injuries resulting in homeostatic changes that are proportional to the size of the burn 10 
injuries.43 Resulting hypermetabolism and catabolism increase the nutrition needs (energy, 11 
protein, and micronutrients), while oxidative stress and large exudate losses from the burn 12 
wounds drive major fluid and TE losses. It is therefore vital that burnspatients receive 13 
additional micronutrients, even if not on PN provision.43 14 
 15 
 16 
For small burns (defined as those <20% BSA), micronutrient maintenance doses (as defined by 17 
DRI or local equivalent indicating daily balanced needs) seem sufficient.44 For major burns  18 
>20% BSA systematic micronutrient repletion is recommended from admission.43 The 19 
requirements typically differ according to the treatment phase:  TE losses must be repleted for 20 
2-3 weeks from admission, and decrease with wound healing.43 21 
 22 
 23 
Early resuscitation phase: Vitamin C has been identified as having a potential role in reducing 24 
fluid resuscitation requirements through stabilizing the endothelial membrane against 25 
increased permeability.45 Vitamin C can be safely used without an increased risk of renal 26 
failure.46  27 
 28 
 29 
Wound healing phase: Micronutrient status is particularly vulnerable during the active healing 30 
phases of burns – this is particularly true for micronutrients involved in antioxidant pathways.47 31 
48 Large TE losses (particularly of Cu, Se and Zn) in wound exudates have been demonstrated 32 
during the first week post injury49 41, while active repletion of these TEs have resulted in 33 
reduced infectious complications, improved skin graft take, and reduced length of ICU stay.50 51 34 
Proposed Se repletion doses of 700 µg/d IV have been shown to be safe for 2-3 weeks (burns 35 
>20% and 50% BSA respectively) and do not require specific blood concentration monitoring.  36 
Additional considerations during this phase include the impact of other supportive therapies. 37 
CRRT of greater than 2 weeks duration has been shown to increase the risk of Cu depletion, 38 
and warrants regular monitoring.52 (See Table 2 for other micronutrient considerations of 39 
CRRT).  40 
 41 
In 1986, Boosalis et al were the first to show that the Se status of major burn patients was 42 
severely compromised.47 In 1991, Cunningham et al showed severe Cu deficiency in extensively 43 
burned children. 48  Balance studies conducted in Lausanne showed that previous reports on 44 
Cu, Se and Zn deficiencies in burns settings53 were the result of early large exudative losses of 45 
TEs during the first week post-injury, particularly for Cu, Zn53 and Se.49 41 Randomized 46 
controlled repletion trials with Cu, Se and Zn doses calculated to compensate the measured 47 
exudative losses initiated upon admission resulted in clinical benefits, such as reduction of 48 
infectious complications, improved skin graft take, and reduction of length of ICU stay.50 51 49 
Recently the Lausanne group published a dose finding study conducted in 139 patients with 50 
burns injuries on 35% BSA showing that their actual IV repletion protocol was safe and 51 
normalized Cu and Zn concentrations.54 Despite the oxidative stress present in major burns the 52 
845 ug/d Se doses delivered until 2016 resulted in supra-normal Se concentrations, suggesting 53 
a reduction to 700 ug/d: this dose proves safe for the described durations, and do not require 54 
specific blood concentration monitoring. Nevertheless, in case of CRRT exceeding 2 weeks in 55 
major burns, the additional high risk of Cu depletion due to prolonged effluent losses55 requires 56 
weekly Cu blood monitoring in locations where timely laboratory support is possible.52 Copper 57 
deficiency, in the presence of inflammation where increased levels are normally found29 56 58 
requires immediate corrective action.21 59 
 60 
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Recovery/rehabilitation phase: Vitamin D deficiency has been demonstrated in major burns and 1 
is caused by skin damage and absence of sun exposure.57 The standard DRI doses are 2 
insufficient to cover the needs and maintain circulating Vitamin D within normal ranges.58 3 
However, a systematic addition of supra-nutritional doses has not been recommended so far.  4 
 5 
 6 
Q6: When should intravenous micronutrients be provided to surgical patients? 7 
 8 
Recommendation:  9 
 10 
M icronutrient abnormalities are common following some gastrointestinal tract (GIT) surgeries. A 11 
clear understanding of the remaining anatomy is important to anticipate changes to absorption 12 
or metabolism of individual micronutrients. 13 
PN is indicated only when the gut is not functioning or if enteral feeding is not safe.  This would 14 
therefore require micronutrient addition to the PN. 15 
 16 
 17 
Rationale:  18 
 19 
A thorough knowledge of the GIT absorption sites for the various micronutrients is essential to 20 
predict potential deficiencies due to malabsorption post GIT surgery. Figure 2 depicts the most 21 
common absorption sites for micronutrients, and Table 3 summarizes the most common 22 
micronutrient deficiencies that can develop post GIT surgery due to the area resected. 23 
Complications following surgery could also impact micronutrient losses. Patients developing 24 
enterocutaneous fistulae (ECFs) can have excessive losses of Zn and Se2 18, whereas patients 25 




Zinc requirements are increased in intestinal and biliary losses, including fistulae, severe 30 
diarrhoea and chyle leaks, as well as sepsis, hypercatabolic states and burns, where additional 31 
supplementation is required.60  Replacement of about 12 mg of Zn per litre of GIT losses in 32 
patients with fistulae, stomas and diarrhea has been recommended.23  Additional Zn, over and 33 
above the daily recommended parenteral doses, may be added to short-term IV infusions in at-34 
risk patients, however, it must also be noted that there is inadequate published information on 35 
the compatibility between injectable Zn solutions and other IV admixtures. As Zn is readily 36 
absorbed in the duodenum, the enteral route may be used if this part of the intestine is 37 




Vitamin K deficiency may be unrecognized, as the laboratory test for coagulation (Prothombin 42 
time, International Normalized Ratio or INR) may not be sensitive enough to detect subclinical 43 
deficiency states, which can become unmasked after surgical procedures or resuscitation.  44 
Antibiotics often alter the intestinal flora and potentially decrease the bacterial production of 45 
vitamin K. If the patient is also nil per os (NPO) the usual oral source of vitamin K is not 46 
available. Some MV preparations may contain insufficient amounts of vitamin K or none at all.  47 
Small amounts of vitamin K, although highly variable with the product being used, are available 48 
from fat emulsions, but cannot be relied upon. The prudent clinician should consider additional 49 
parenteral vitamin K (IM or added to PN) whenever the clinical situation demands it, especially 50 
prior to elective surgery, irrespective of laboratory tests. A weekly dose of 250 – 400 µg is 51 





Selenium deficiency may occur with GIT, bile or chyle losses or when Se is not added to PN.  57 
Chylous fistulae, for which PN is often required, result in micronutrient losses due to the large 58 
volumes of protein-rich fluid being lost. Selenium deficiency secondary to these losses has been 59 
reported and it is highly likely that other TEs are also lost.59 Selenium is not a component of 60 
MTE admixtures in some countries.  However, it is an important essential TE, with major anti-61 
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oxidant functions. It is recommended that patients with small bowel resection, inflammatory 1 
bowel disease or other intestinal disorders should have their Se level checked prior to starting 2 
PN and every 3 months if deficiency is found.63 When Se deficiency is suspected based on 3 
clinical presentation or laboratory tests, clinicians should first make sure that the MTE 4 
admixture does indeed contain Se. Pharmacologic doses of Se for specific conditions have been 5 




Bariatric surgery, and especially malabsorptive procedures, can result in many micronutrient 10 
deficiencies. This includes fat-soluble vitamins (A, D, E, K), water-soluble vitamins (especially 11 
vitamins B1, B6 and B12), as well TEs (Fe, Cu and Zn).
2  It is recommended that micronutrient 12 
status should be determined prior to and after bariatric surgery. 65 . This should begin at least 13 
one month before the procedure and continue lifelong thereafter.65 Pre- and post-bariatric 14 
surgery nutrient screening and supplementation recommendations to prevent and treat 15 
micronutrient deficiencies are available.65 66  16 
 17 
 18 
It is clear that surgery, inclusive of bariatric surgery, could have direct consequences on 19 
micronutrient status and additional micronutrient requirements are needed in cases of wound 20 
healing. However, in cases of a functional gut, micronutrient correction can be done via the oral 21 
or enteral route. In general an adequate supply of micronutrients is considered essential for 22 
any surgical patient on long-term PN. 67 The route of supplementation will be dictated by the 23 
adequate functioning of the GIT. 24 
 25 
 26 
Q7: What are the roles and importance of micronutrients in home parenteral nutrition? 27 
 28 
Recommendation:  29 
Micronutrients provided as part of an individually prescribed home parenteral nutrition (HPN) 30 
formulation are essential to patients with long term HPN requirements and may represent the 31 
only reliable source of micronutrient provision and replacement. Monitoring of micronutrient 32 




Rationale:  37 
Micronutrient status of HPN patients has traditionally been a focus of concern 68, and levels 38 
continue to be demonstrated to be vulnerable.69 Therefore micronutrients need to be seen as 39 
an essential component of HPN provision18,19,70, and in some cases may be the only reliable 40 
source of micronutrient provision in this population. Unless otherwise clinically indicated they 41 
should be provided with each bag of HPN.19 42 
 43 
 44 
Due to the long term nature of HPN provision, monitoring of micronutrient status is required at 45 
baseline and at 6 to 12 month frequency18,19,70 to detect deficiency and/or toxicity states. The 46 
frequency can vary according to changes in clinical status and micronutrient prescription.19 47 
Individualised prescriptions and supplementation courses need to be modified according to 48 
micronutrient levels and their trends as well as the clinical situation.18,19,70  49 
 50 
 51 
In HPN patients, vitamin D levels should be monitored every 12 months and corrected 52 
accordingly (IM, separate IV infusion or higher PN dose).19 Bone mineral density measurements 53 
should also be done annually in long-term HPN patients.71 54 
 55 
 56 
Micronutrient prescription for HPN patients, as all aspects of HPN management, should be 57 
overseen by a multidisciplinary nutrition support team (NST) with skills and experience in 58 
managing intestinal failure and HPN.70 Micronutrient prescriptions for HPN patients should be 59 
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individually tailored in response to monitoring and clinical changes throughout the duration of 1 
a patient’s HPN journey.18,19,70 Factors requiring consideration include:  2 
 3 
 Vulnerable M micronutrient status at baseline/HPN commencement,  4 
 Micronutrient losses or malabsorption due to anatomical considerations (e.g. fistulae, 5 
altered GIT anatomy, etc.) or increased physiological turnover due to concurrent comorbid 6 
conditions (e.g. for wound healing, chronic inflammation etc.),  7 
 Alterations to micronutrient excretion that may require reduced doses or omission of some 8 
micronutrient (e.g. such as may occur in cholestasis, chronic kidney injury, etc.), and 9 
 The degree to which oral or enteral intake may contribute to the partial provision of some 10 
micronutrients, and the changes that may occur in this over time in the setting of natural or 11 




Q8: How should micronutrients be provided intravenously? 16 
 17 
 18 
Recommendation:  19 
Various PN admixtures are available around the world, however, the composition of these 20 
admixtures differ, the majority being without micronutrients. It is essential that micronutrients 21 
be administered together with any PN prescription.2,17,19,30,64,72 These can be added to the PN 22 
formulae, or administered directly to patients via IV fluids.30 Due to chemical stability, vitamins 23 
and TEs sometimes need to be added to PN admixtures separately, or be compounded in 24 




Rationale:  29 
Issues of compatibility and stability must always be considered when providing micronutrients 30 
concurrently with PN formulations. By definition ready-to-use PN formulations contain no 31 
micronutrient, except in case of compounding, and the latter implies limited stability of the PN 32 
formulation. It is essential that micronutrients be administered daily with PN: failure to do so 33 
may affect substrate bioavailability, metabolic function and clinical efficacy.73–76 Formulations 34 
of micronutrient admixtures vary by region, and these differences may impact chemical 35 
stability and subsequently mandate specific methods by which individual combinations are 36 
added to PN.18,19 It is therefore essential that clinicians and technicians involved with this 37 
process have knowledge about the dose, incompatibilities, stability and skill to administer 38 




In the absence of strong evidence in the literature comparing the efficacy of different methods 43 
of micronutrient delivery in conjunction with PN formulations, decisions of how best to 44 
administer IV micronutrients are in practice based on organisational policy and/or facility 45 
capabilities. Common options for micronutrient provision include: 46 
 Incorporation into PN formulations at the time of initial compounding (commercial 47 
facilities, hospital pharmacy); 48 
 Addition to individually compounded or commercially available ready-to-use PN 49 
formulations closer to the time of provision under sterile conditions (commercial facilities, 50 
hospital pharmacy); 51 
 Micronutrient provision separate to PN formulation, but within the same 24hr period, such 52 
as through side lines during PN infusion or prior to the commencement of PN provision. In 53 
these cases micronutrients should ideally be delivered over the maximum time period 54 




with the administration recommendations provided by the manufacturer (hospital pharmacy, 59 
ward level). 60 
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 Micronutrients can be given via central or peripheral veins. Concentrated multiple TE 1 
admixtures must be diluted appropriately and administered slowly and never given as 2 
bolus administration. The manufacturer’s directions for dilution and administration and 3 
compatibility with other components must be followed. 4 
 5 
 6 
Various situations of micronutrient losses associated with PN delivery have been reported. 7 
Inadequate micronutrient provision may occur through the incomplete infusion of the full bag 8 
of PN to which the micronutrients have been added. A further means of micronutrient activity 9 
loss of photosensitive micronutrients (vitamins A, C and E) may come through photo-10 
degradation through contact of UV light.77 If sunlight exposure is a consideration, e.g. 11 
ambulatory patients receiving PN as inpatients or home PN patients, there is the potential for 12 
detectable loss of vitamins A and C  from the infusion77 78 and light protective coverings can be 13 
used during infusions to avoid nutrient losses.19 This is however not a routine practice in the 14 




When micronutrients are added to the PN formulation prior to infusion, in-bag losses of 19 
vitamin activity due to oxidation and interactions must be considered. Varying 20 
recommendations exist as to how to manage this, which range from addition of IV 21 
micronutrients to PN formulations soon before infusion, to infusing TE and vitamin components 22 
separately to minimise losses.68 However further research is required to provide clear evidence 23 
based guidance regarding this.  24 
 25 
 26 
Inadvertent TE contamination from individual PN components has historically been considered 27 
as an additional source of TEs in PN formulations above MTE provision. However it is unclear to 28 
what degree TE contamination patterns have changed with the evolution of storage and 29 
handling practices of PN and micronutrient components in recent decades.19 Manufacturers of 30 
individual PN components should carefully monitor and describe TE contamination in their 31 





Irrespective of the methods utilized, the establishment of regulations and handling standards 37 
for pharmacy and healthcare services involved with PN provision are essential to safeguard 38 
sterility of introducing micronutrient to PN formulations, as well as stability and compatibility 39 
considerations due to the high-risk nature of PN as a nutritional intervention.72 These standards 40 
should be guided by Good Pharmaceutical Manufacturing Practice82 and include specifications 41 
regarding the characteristics of the physical areas, equipment and the knowledge and skills of 42 
the personnel who make the mixtures for PN. The standards should also be updated 43 




For patients with longer term PN requirements, such as those requiring HPN who may have 48 
some residual gut function, oral or enteral supplementation may be feasible depending on 49 
their remaining anatomy and other clinical factors. The risk of not meeting requirements is 50 
therefore greater via the EN route30, and IV options should be favoured unless evidence of 51 
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 1 
Q9: What are the challenges in administering Intravenous micronutrients?  2 
 3 
 4 
Recommendation:   5 
Equity of consistent access to IV micronutrient preparations must become an international 6 
priority to support clinicians to provide safe PN and to be able to respond with clinically 7 
appropriate replacement therapies for patients with non-functioning guts.  8 
 9 
Rationale:   10 
Individual IV forms of various micronutrients are not freely available in all countries and 11 
provide challenges in correcting abnormal values.2 For instance, Zn, I and Se are not available in 12 
parenteral form in many countries. Under these situations, clinicians have no alternative than 13 
to provide micronutrient enterally or orally in an attempt to meet patient requirements. This 14 
approach is fraught with risk as alteration of oral preparations (i.e. crushing tablets,  piercing 15 
gelcaps and allowing contents to dissolve sublingually) is often required to allow 16 
administration, and when PN is indicated, case reports have demonstrated the lack of 17 
effectiveness of oral/enteral routes to adequately provide micronutrient requirements.84 18 
Equitable access to IV micronutrient preparations and individual micronutrients are required 19 
for safe clinical practice and must be an international priority to allow the safe and appropriate 20 






Another issue is the intermittent shortages of micronutrients which are significant challenges 27 
for clinicians trying to provide safe and effective PN. North America has periodically 28 
experienced shortages of IV micronutrients over the last 30 years.85 The reasons for this include 29 
regulatory issues, natural disasters, voluntary recalls, issues with raw materials, increase in 30 
demand, discontinuation, loss of manufacturing sites, and quality issues.85 Mortality and 31 
morbidity associated with these shortages are acknowledged, with the most well described 32 
being complications of thiamine deficiency (fatal episodes of lactic acidosis, Wernicke’s 33 
encephalopathy and beri beri).84 86  However a variety of other clinical manifestations have also 34 
been reported including Cu deficient anaemia and hyposelenemia.87 ASPEN has provided 35 
guidance on how to minimise clinical risk to patients in cases of periodic micronutrient 36 
shortage88 89, and the FDA and other agencies are taking steps to improve the continuity of 37 
access of injectable drug products.85 90 While these steps are helpful, rectification of the 38 
underlying causes for the shortages are critical to safe provision of PN. Further discussion of the 39 
topic and resources to assist clinicians in navigating shortages of PN components have been 40 






Q10: Who is responsible for prescribing intravenous micronutrients? 47 
 48 
Recommendation:  49 
The clinician responsible for prescribing and/or charting the PN macronutrient formulation(s) is 50 
ultimately responsible for prescribing the IV micronutrients to ensure complete nutrition is 51 
provided. This, as for all aspects of PN, should occur as part of a multidisciplinary Nutrition 52 
Support Team (NST) governance of PN. Where NSTs do not exist, the advocacy for the 53 












Rationale:  4 
The value of a multidisciplinary team-based approach to the provision of nutrition support 5 
including PN is well established, with demonstrated benefits including improved adherence to 6 
evidence based practice, improved clinical outcomes and financial savings.91 92 The clinician 7 
who initially enters a PN order, irrespective of the discipline (physician, nurse, dietitian or 8 
pharmacist) is ultimately responsible for including orders for micronutrient additives, both MV 9 
and MTEs.  Although regulations vary in geographic areas, in most countries a physician’s order 10 
is required for PN.  However, the physician may not have specific nutrition support training and 11 
may depend on the recommendations from members of a NST who have. When PN is 12 
compounded by pharmacists, yet another opportunity is available to assure addition of 13 





It is crucial that all NST members have adequate knowledge  about the functions and 19 
requirements of micronutrients in patients receiving PN to avoid deficiencies and excess.17 72. In 20 
facilities where PN is compounded on site, the pharmacist is responsible for the PN admixtures 21 
preparation and should participate in the development and adherence to policies and 22 
procedures related to the compounding and delivery of safe and effective PN formulations. 23 
72,73,95 Similarly, sound knowledge about Good Pharmaceutical Manufacturing Practice82 in 24 





Q11: How and when should micronutrient status be assessed /monitored? 30 
 31 
Recommendation: 32 
Micronutrient status assessment is recommended for vulnerable populations of patients with 33 
high index of suspicion for micronutrient deficiencies or toxicities. This patient group include 34 




The following should be considered in the assessment of micronutrient status:  39 
 (a) clinical manifestations of symptoms that may suggest micronutrient abnormalities,  40 
(b) appropriate laboratory examinations coupled with other tests such as CRP that may 41 
render results invalid or unreliable. 42 
 43 
 44 
Monitoring of micronutrient status is recommended when active correction has taken place and 45 
when a patient is on long-term PN.  Frequency of monitoring and the parameters or tests to be 46 




As the concurrent provision of MV and MTE supplementation with PN should provide 51 
micronutrient requirements serum levels of MN do not require routine monitoring in patients 52 
receiving short term PN. 2 19 53 
 54 
When monitoring is required, laboratory testing to guide micronutrient provision include 55 
serum,  plasma or whole blood levels, or enzyme function.96 There is, however, a lack of 56 











to the optimal measures to use to assess status of specific micronutrients.96 The availability and 5 
methods of testing vary widely between micronutrients and between regions, and clinicians are 6 
advised to liaise with their local laboratories and clinical experts for advice on what is available. 7 
In addition, micronutrient testing is often expensive18 19 and, therefore, judicious assessment 8 




The decision to assess micronutrient status with biochemical measures may be considered in a 13 
number of clinical situations.18 19 These include where a high degree of clinical suspicion exists 14 
due to:  15 
 Pre-existing lifestyle factors (self-neglect, alcohol and substance abuse, etc.)  16 
 Clinical conditions that may increase micronutrient losses or requirements (malnutrition, 17 
altered GIT anatomy, critical illness, trauma, burns) use of medications (anticonvulsant and 18 
anti-retroviral therapies), baseline levels in long term PN, etc. 19 
 Clinical conditions that may predispose to retention of micronutrients or their metabolites 20 
(renal or liver failure2 30, cholestasis, etc.) 21 
 Known regional or cultural predisposing factors (regional endemic vulnerability such as 22 
Iodine in Australia and New Zealand; Vitamin D deficiency in long term hospitalised 23 
patients, factors that limit skin exposure to UV light (skin pigmentation, cultural or religious 24 
clothing customs), regions with less sunlight during winter months; Fe deficiency in the 25 





The decision to monitor micronutrient status biochemically may be considered in clinical 31 
situations that represent 32 
 Follow up after micronutrient replacement therapies are provided19 33 
 Routine surveillance of patients receiving long term/home PN18,19,70  34 
 In cases of organ failure (liver or kidney), danger of toxicity necessitates monitoring.2 30 35 
Renal function should be considered when vitamins and TEs are supplemented.64 36 
 In case of prolonged (>2 weeks) CRRT21,22 a monthly monitoring of hydrosoluble 37 




If micronutrients are included with macronutrient provision (i.e., each day  PN is provided) and 42 
have been prescribed in consideration of the individual clinical requirements, the risk of 43 
developing micronutrient complications is low, and isolated micronutrient monitoring may be 44 
of limited value in otherwise stable patients in the acute setting.18,19 Therefore, careful 45 
consideration of the clinical significance of micronutrient testing needs to be considered in the 46 
acutely unwell patient, and routine measurement of serum vitamin levels is not usually 47 
recommended in critical care.2 If micronutrient testing is considered to be appropriate, it 48 
should always be done in conjunction with a concurrent CRP level to allow interpretation.18 19 49 
(Refer to question 4 and Table 1). Similarly, the time elapsed from the last provision of IV 50 
micronutrient infusion to the timing of the sample collection should be considered in the interpretation 51 
of results. It is unfortunately not possible to provide  a definite time period, since the infusion of 52 
micronutrients are sometimes done simultaneous to PN (in which case there is no time lapse) or the 53 
infusion can be separate from PN and given over 6 houts. In the latter case, a time lapse of 2 hours can 54 
be implemented before blood sampling. 55 
 56 
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The Australian PEN society (AuSPEN) Trace element Guidelines (2014) and Vitamin Guidelines 1 
(2016) provide an outline of clinical considerations for when and how to biochemically assess 2 
individual micronutrient in the setting of PN.18 19 3 
 4 
 5 
Q12: What are the consensus recommendations for micronutrient administration to 6 









Recommendation:  16 
ASPEN17, AuSPEN18 19 and ESPEN67 have produced evidence-based documents that provide 17 
recommendations regarding micronutrient practice in the context of PN. Guidelines addressing 18 
PN micronutrient provision highlight the need to provide micronutrients daily together with PN 19 
and individualisation of micronutrient requirements and monitoring in long term PN. Consensus 20 
recommendations for routine micronutrient administration via PN formulations from our group 21 




Rationale:  26 
Due to the essential role of micronutrients in metabolism, micronutrients should be provided 27 
daily in conjunction with PN to prevent the development of deficiency. Contemporary 28 
commercial MV and MTE preparations currently available meet the recommendations for most 29 
patient groups and should be used as a first line provision. Consideration of additional 30 




While there are some minor differences between these international guidelines owing to 35 
variation in methodology in the development process, clinical focus of guidelines, and/or 36 
regional vulnerability with regard to specific micronutrient deficiency, they all agree in principle 37 
on key overarching factors: 38 
 39 
 40 
1. Micronutrients are essential components of PN, without which the nutrition provided is 41 
metabolically incomplete. As such they should be provided from day one of PN 42 
commencement until PN cessation. 43 
2. Micronutrient prescription should be individualised to the clinical requirement of the 44 
patient. 45 
3. Micronutrient status should be monitored in long term PN patients at baseline and 6 to 12-46 
month intervals thereafter.19 67 At risk patients may be monitored at the discretion of the 47 




Toxicity due to increased administration of fat-soluble vitamins can occur. A safe intake level is 52 
10 times DRI. Up to 100 times DRI intake can be safely handled for water-soluble vitamins such 53 
as thiamine and vitamin C with toxicity development highly unlikely especially with short term 54 
administrations. For TEs caution should be given not to exceed 10-15 times the DRI for periods 55 
exceeding a few weeks.2 Additional vitamin E is added to PN formulations containing high 56 
quantities of PUFA’s to combat lipid peroxidation rendering systematic addition unnecessary. 19 57 
Clinicians, therefore, need to be familiar as to whether the routine addition of vitamin E to PN 58 
formulations occurs during compounding in their local setting, as higher maintenance doses 59 
may need to be prescribed for patients receiving second and third generation lipids without 60 
vitamin E added during compounding to compensate for in-bag losses. 61 




Additional considerations around individual micronutrient such as supplementation dosages, 3 
conditions requiring additional levels, dangers of toxicity and monitoring guidelines are 4 








Q13: Are there any risks associated with intravenous micronutrient provision at routine 13 
parenteral nutrition dosages?  14 
 15 
 16 
Recommendation:  17 
The highest risk regarding routine doses is not delivering them with PN. There are few instances 18 
in long term PN where the choice of parental micronutrient products administered should be 19 
carefully considered. In certain conditions, e.g. Mn encephalopathy and hemochromatosis (Fe) 20 
individual trace elements may need to be omitted and not routinely administered. 21 
 22 
Rationale: 23 
Routine doses of Fe belong to standard practice amongst patients with intestinal failure or with 24 
very limited oral Fe absorption capacity (e.g., due to extensive resection of the upper GIT), as 25 
this element is essential.  However, the optimal IV maintenance Fe regimen in the absence of 26 
anemia associated with chronic kidney disease (e.g., short bowel syndrome, bariatric surgery) 27 
warrants further investigations.  It must be noted that IV Fe administration bypasses the 28 
normal regulatory mechanism of Fe bioavailability and homeostasis in the GIT.  Since the daily 29 
turnover of Fe is low in most patients without anemia or chronic bleeding, oversupply of IV Fe 30 
risks causing Fe overload, increased oxidative stress, and infectious complications.  Determining 31 
additional requirements in critically ill patients is difficult as inflammation alters Fe regulation 32 
and affects the accuracy of its laboratory assessments (e.g. ferritin).   The prevalence of real Fe 33 
deficiency on ICU discharge, distinct from the inflammation sequestration issue, is elevated and 34 
contributes significantly to fatigue observed after discharge.99 Recently a better understanding 35 
of Fe metabolism has shown that blood hepcidin may assist in diagnosing Fe deficiency in the 36 
presence of inflammation100 and is currently under investigation.101 The benefits of short-term 37 
IV supplementation (0.5-1 g for a few days) in reducing transfusion requirement have not yet 38 
been proven102, but the trials have shown no increase in infectious complications102 103, which 39 
were previously considered a prohibitive risk.  It is therefore prudent to provide Fe to critically 40 
ill patients only in cases of proven Fe deficiency (which is best defined by hepcidin levels)100 and 41 






Cu and Mn are excreted in the bile. In patients on long term PN with hepatic failure, it is 48 
prudent to limit these TEs prior to obtaining serum levels. In addition, there are cases of Mn 49 
toxicities reported in long-term PN patients with magnetic resonance imaging of the brain 50 
showing Mn deposition in the basal ganglia (Mn encephalopathy).104 This can be associated 51 
with neuropsychiatric symptoms and parkinsonism105 which can be reversed upon removing 52 
Mn from PN .106 The newer commercial MTE available in some parts of the world have lower 53 




Patients with renal failure are at potential risk of vitamin A toxicity due to reduced excretion. 68  58 
In case of prolonged PN, both excessive and insufficient levels may be observed, which may 59 
justify dosing vitamin A in plasma on a annual or bi-annual frequency. 60 
 61 









Q14: Are there specific micronutrient risks upon initiation of parenteral nutrition? 8 
 9 






The rapid reintroduction of glucose (such as commencing on full dose PN or high dose glucose 16 
infusion) to a patient experiencing starvation may precipitate refeeding syndrome. Thiamine is 17 
the main micronutrient implicated in refeeding syndrome complications. 18 
 19 
 20 
Though rare, there have been reports of hypersensitivity reactions developing to vitamins 21 
and/or their components provided intravenously. 22 
 23 
 24 
Rationale:  25 
For a detailed review of refeeding syndrome see Boateng et al 2010.107 Thiamine 26 
administration should be provided as a loading dose (300mg/d IV) prior to nutrition 27 
commencement, followed by a maintenance dose of 100 mg/d during nutrition to avoid 28 
deficiency complications developing. Broader MV and MTE supplementation should also be 29 
considered due to the risk of broad micronutrient vulnerability in patients at risk of refeeding, 30 
and concurrent micronutrient supplementation is essential in those receiving PN. 31 
 32 
 33 
Hypersensitivity reactions to PN are uncommon.  However, case reports have identified the 34 
component, thiamine, vitamin B complex, vitamin K and magnesium sulfate as likely causes of 35 
hypersensitivity reaction. Polyoxyethylated fatty acid derivatives, similar to Cremophor EL, can 36 
also be found as a vehicle for fat soluble vitamins leading to C activation-related pseudoallergy 37 
(CARPA). In addition, the inactive component, polysorbate, is believed to be a primary cause of 38 
hypersensitivity. Other case reports have identified the lipid emulsion component as the 39 
causative agent.108  The option in these cases with regard to vitamins (not TE), might be to 40 
resort to modular assembly of a panel of vitamins which conforms to patient’s requirements if 41 
using single-entity products in lieu of commercial bundled micronutrient products. But there 42 
are currently no studies available. When vitamins or trace elements cannot be added to PN for 43 
hypersensitivity reasons, it can be given enterally in situations where the GI tract is accessible 44 







Conclusion and call to action 52 
This expert consensus paper has sought to highlight the importance of micronutrient provision 53 
as an integral, daily part of safe and responsible PN provision. It has also attempted to translate 54 
the intent of the existing guidelines available as they pertain to micronutrient provision in a 55 
range of PN patient populations into practical terms. It is our hope that this will assist with the 56 
adoption of evidence based recommendations irrespective of the level of experience of the 57 
clinician providing the PN intervention.  58 
 59 
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In terms of advocacy, there are a number of calls to action we wish to draw attention to. These 1 
affect the international nutrition community, the organisations they exist in, and the industries 2 
that support them. 3 
1) The recognition that micronutrient must be provided daily from the commencement of PN 4 
macronutrients to provide safe and complete nutrition, and that failure to do so will pose 5 
nutritional risk. Delays to micronutrient commencement, their voluntary omission or partial 6 
provision is unacceptable practice that must be abandoned, and any additional cost 7 
considerations must be considered as inclusive of the PN provision.  8 
2) The acceptance that PN is not the only indication to prescribe IV micronutrients. There are 9 
other high-risk groups (e.g. inadequate enteral intake, excessive losses) that also 10 
necessitate additional micronutrients. 11 
3) The imperative of having required IV micronutrient preparations – in individual or MV/MTE 12 
preparations – available within all markets in which PN is provided, and in consistent 13 
supply, cannot be understated as an essential element to the safe provision of PN. Steps 14 
must be taken to resolve the current discrepancies of regional access and inconsistency in 15 
supply. 16 
4) Coupled to adequate supply of IV micronutrient preparations, the importance of ensuring 17 
that the available products comply to the evidence-based recommendations in terms of 18 
composition. 19 
5) More research should be conducted on the following: 20 
a. Method of administration of PN micronutrients  21 
b. Current situation with TE contamination in current compounding methods 22 
c. Compatibility and stability of micronutrients, especially TE solutions 23 
d. Multiple MN requirements in patients with special needs such as in the ICU 24 
e. Development of affordable assays to determine multiple micronutrient levels  25 
6) Commitment to provide advanced nutrition support training for clinicians to promote and 26 
deliver safe PN practice 27 
 28 
Ultimately micronutrients need to be understood as a critical component to nutritional 29 
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Table 1: Impact of metabolic stress on micronutrient status  2 
 3 
Micronutrient Effect of acute phase response 
Copper  Increased Copper serum levels.18,29,31  Pro-inflammatory cytokines 
stimulate the acute phase response. More copper is needed for 
increased ceruloplasmin synthesis, which is required for iron transport. 
 Serum copper levels should be interpreted in the context of 
inflammatory markers (e.g. CRP).18 
Iron  Decreased serum iron levels to ensure that less circulatory iron is 
available for bacteria to thrive on and to decreased oxidative damage 
to cells 2,18,29–31 40 33 
 Increased ferritin (store) levels 18,29,31,66 40 33 
 Serum iron levels should be interpreted in the context of inflammatory 
markers (e.g. CRP).18 
Selenium  Decreased serum levels 2,18,29–31,64 33 36 in proportion to the magnitude 
of the inflammatory response and also due to increased urinary losses 
 Serum Selenium levels should be interpreted in the context of 
inflammatory markers (e.g. CRP).18 
 Selenium concentrations can only be interpreted if CRP levels are <10 
mg/L. 32  31 In presence of inflammation, and in absence of glutathione 
peroxidase determination, only very low values of Selenium (< 50% of 
reference value) should be considered as reflecting deficiency. 
[Colleagues, do we have a reference for this?] 
Zinc  Initial serum increase due to tissue damage that results in excessive 
zinc  release 29 
 Followed by decreased serum levels due to increased losses (skin, 
urine and stool) and decreased serum albumin levels. Albumin is a 
negative acute phase protein and since zinc is bound to albumin for 
transport, decreased albumin levels will result in less available 
zinc.2,18,29–32,64 33 36 
 Redistribution of zinc also results in an increased accumulation of zinc 
in the liver where it acts as co-factor for acute phase protein (APP) 
synthesis. 
 Serum zinc levels should be interpreted in the context of inflammatory 
markers (e.g. CRP). 18 32 
 A reliable Zinc deficiency interpretation can only be made if serum CRP 
levels are < 20mg/L. 31,32 Very low levels <50% below reference values 
should always be considered as suspect of deficiency [Colleagues, do 
we have a reference for this?] 
 Excessive Zinc supplementation can induce copper deficiency. 
Vitamins - 
general 
 Decreased serum levels due to increased requirements (which could 
be due to increased metabolic rate and also because vitamins are used 
for biochemical functions during the acute phase response e.g. protein 
metabolism), increased catabolism, malabsorption, increased urinary 
losses and potential drug interactions.29 
 May return to normal serum levels after infection resolves without any 
treatment. For instance, vitamin A is bound to retinol-binding protein 
(RBP) for transport. Albumin (a negative APP) status will normalize 
after infection clears and hence vitamin A levels will improve.29 
Vitamin A  Vitamin A decreases during the acute phase because retinol binding 
protein acts as a negative acute phase protein.29,31 36 
Vitamin B1 – 
Thiamine 
 Increased requirements for Vitamin B1 may be needed during periods 
of increased metabolic stress and increased dietary carbohydrate 
provision.19 
 Serum levels not affected by periods of inflammation.2 
Vitamin B2  Serum levels not affected by periods of inflammation.
2 
Vitamin B6  A decrease in serum vitamin B6 is seen with only a slight increase in 
CRP ( 5-10 mg/L)32 36; therefore caution should be taken when 
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interpreting true deficiency 
Vitamin B12  Serum levels not affected by periods of inflammation.
2 
Vitamin C  A decrease in serum Ascorbic acid 31 33 36 is seen with only a slight 
increase in CRP ( 5-10 mg/L)32  
 Therefore caution should be taken when interpreting true deficiency 
 Decreased plasma concentrations are seen within 24 hours post acute 
injury 110 
Vitamin D  A decrease in serum 25(OH)-vitamin D is seen with only a slight 
increase in CRP ( 5-10mg/L)32 33 36, therefore caution should be taken 
when interpreting true deficiency 
Vitamin E  Circulating Vitamin E declines modestly during inflammation 19,31 33 36, 





Table 2: Micronutrient considerations for critical illness beyond provision of daily 5 
maintenance MTE provision. 6 
 7 
Copper  Negative copper balances have been demonstrated in CRRT20 22 55 111 
with copper losses of up to 6.5 µmol/24hrs on CRRT reported 55 
Iron  Despite iron deficient anaemia being commonly observed during critical 
illness, this is multifactorial and may represent a beneficial adaptive 
change during critical illness.  
 There are presently no recommendations to manage iron deficiency 
with iron as a monotherapy.103,112 
Selenium  Selenium supplementation has been studied in sepsis and septic shock 
with mixed findings, and high dose, supra-physiological 
supplementation is not presently recommended in critically ill patients. 
20 113 
 Negative selenium balances have been demonstrated in CRRT55 111, with 
losses of up to 1 µmol/24hrs of CRRT reported.55 
Zinc  Zinc is recognised to be a vulnerable trace element in the critically ill 
that should be monitored and replaced if underlying deficiency or high 
risk of developing a deficiency is suspected114 
 However no recommendations currently exist to guide optimal zinc 
dosing in the critically ill (IV or otherwise)115 






 Supplemental vitamin and trace element combinations (Zn, Se, Vits A, C, 
E, N-acetylcysteine, provided via EN or IV or combination) are not 
recommended in critically ill patients.113 
 In major burns, combination of Cu, Se, Zn, Vitamin C in doses 5-10 times 
DRI combined with standard multimicronutrient are provided IV during 
the first 2-3 weeks and result in normalisation of antioxidant function.43 
Vitamin B1 - 
Thiamine 
 Thiamine is emerging as an increasingly important vitamin in the 
management of sepsis. Normalising thiamine levels during septic shock 
may reduce mortality and reduce progression to renal replacement 
therapies although these results require validation.117  
 High thiamine losses have been demonstrated with CRRT and thiamine 
supplementation should be considered in this patient group to avoid 
the development of deficiency.22 55 111 
 Refeeding syndrome may be seen in ICU, particularly with the high rates 
of malnutrition observed in the critically ill. Depending on refeeding 
risk, IV thiamine replacement prior to or together with commencement 
of feeding is recommended in refeeding prevention and treatment.118 
 MV admixtures contain the DRI for thiamine, but this amount may be 
insufficient with a high dextrose load, leading to iatrogenic deficiency 
states. Considering its low risks, a liberal amount of thiamine should be 
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administered in critical care practice at daily dosages of 300 mg IV for 
at-risk patients, and 100 mg in all other patients, during the first 48 
hours of ICU admission.117 
 
Vitamin B6  Patients with acute renal failure requiring CRRT should receive 100mg 
vitamin B6 daily for 3-5 days.
116  
 Monitor serum levels. 
Vitamin C  Vitamin C may be beneficial in times of oxidative stress119 and 
requirements are acknowledged to increase during critical illness117  
 Pharmacological doses may be of benefit in the early stages of critical 
illness117, however these results require validation.113 
 Vitamin C replacement may be of benefit to reverse depletion 
demonstrated during cardiopulmonary bypass120 
 Monitoring of plasma concentrations is recommended in patients 
requiring PN for more 6 months or more 42 
 The risk of nephrolithiasis should be monitored in long-term HPN 
patients68 
 
Vitamin D  Vitamin D levels is recognised to be commonly low in critically ill 
populations and a predictor of outcome. 113,121 117 
 Vitamin D is ineffective in the acute setting.  The 1,25 hydroxy form is 
needed when liver and renal functions are suboptimal.122 Until the 
results on on-going trials are available and accepted  (VIOLET study, NCT 
03096314 and VITDALIZE study, NCT 031188796),  the routine 
administration of additional Vitamin D (by oral or intra-muscular route) 
for patients on short-term  PN cannot be justified.123 
 It should be noted, however, that some papers describing lack of 
benefit of vitamin D in critically ill patients may be flawed in design as 
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Table 3: Potential micronutrient deficiencies following surgical resections of different 2 
segments of the intestine 3 
 4 
GIT Area resected Potential micronutrient deficiency 
Gastric resection  Vitamin D 17 
 Vitamin K 17 
 Iron 2 19 
 Vitamin B12 
2 19  
Gastric bypass surgery  Vitamin K deficiency 17 
 Copper 18 
Gallbladder resection  Vitamins A, D, E and K 2 
Jejuno-ileal bypass surgery  Vitamins A, D, E, K 17,125 Calcium125 
Whipple (pancreatico-
duodenectomy) 
 Vitamins A, D, E, K, vitamin B12 and iron
126 
Proximal jejunum  Duodenum and proximal jejunum – zinc 66, copper 127 
Terminal ileum resection  Vitamin B12 
2,17,19,125 
Short bowel syndrome  Vitamin B2 
17, A, E, K (if colon is resected) 17,19, folic 
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Table 4: Comparison of consensus recommendations for daily micronutrient administration 
 













Australia and New Zealand 





Vitamin A / 
Retinol 
3300 IU (990 μg RE) 3500 IU (1050 μg RE) No recommendation  3300-3500 IU (990-1050 μg RE)  
Vitamin D / 
Cholecalciferol 
200 IU (5μg) 200 IU (5 μg) No recommendation  200 IU (5μg) 
Vitamin E /  
Alpha tocopherol 
10 mg  10 mg No recommendation  10 mg 
Vitamin K / 
phytomenadione 
150 μg No recommendation made:  
Individual assessment 
recommended.  
No recommendation  Individual assessment 
Vitamin B1 / Thiamine 6 mg 3 mg No recommendation  3-6 mg 
Vitamin B2 / Riboflavin 3.6 mg 4-5 mg No recommendation  3.6-5 mg 
Vitamin B3 / 
Niacin 
40 mg 40-47 mg No recommendation  40-47 mg 
Vitamin B5 / 
Pantothenic Acid 
15 mg 16-17 mg No recommendation  15-17 mg 
Vitamin B6 / 
Pyridoxine 
6 mg 3 mg No recommendation  3-6 mg 
Vitamin B12 
Cobalamin 
5 μg 5-6 μg No recommendation  5-6 μg 
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Vitamin B9 /  
Folic acid 
600 μg 400 μg No recommendation  400-600 µg 
Ascorbic Acid /  
Vitamin C 
200 mg 110-150 mg No recommendation  110-200 mg 
Biotin 60 μg 60 μg No recommendation  60 μg 
Zinc (Zn) 39-76 μmol (2.5-5 mg) 50-100 μmol (3.2-6.5mg) 38-61 μmol (2.5-4mg) 39-100 μmol (2.5-6.5 mg)  
Copper (Cu) 4.7-7.8 μmol (300-500 μg) 5-8 μmol (317-508 μg) 4.7-9.6 μmol (0.3-0.5mg) 4.7-9.6 μmol (300-610μg) 
Selenium (Se) 0.75-1.25 μmol (60-100 μg) 0.75-1.25 μmol (60-100 μg) 
 
0.2-0.8 μmol (16-63 μg) 0.25-1.25 μmol (20-100 μg) 
Manganese (Mn) 1 μmol (55 μg) 1 μmol (55 μg) 1.1-1.8 μmol (60-100 μg) 1-1.8 μmol (55-100 μg) 
Iron (Fe) No routine recommendation in 
US 
20 μmol  (1.1 mg) 
may not be necessary 
17.9 mmol (1 mg) 1-1.2mg in those recommending Fe 
Chromium (Cr) 0.2-0.3 μmol (10-15 μg) 0.2-0.3μmol (10-15 μg)  
may not be necessary 
No recommendation 0.2-0.3µmol (10-15 µg) 
Molybdenum (Mo) No routine recommendation in 
US 
0.2 μmol (19 μg)  
probably not necessary 
No recommendation No recommendation 
Iodine (I) No routine recommendation in 
US 
1 μmol (126 μg) 0.5-1.2 μmol (70-150 μg) 0.5-1.2 μmol (70-150 μg)  
in those recommending it 
 








Figure 1: Trace element correction options 
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Figure 2: Micronutrient absorption sites 
 
